Sort   by:  
 Page size 
ProteomicsTHEM6-mediated lipid remodelling sustains stress resistance in cancer (Part2 : THEM6 KO in 22rv1)
Despite the clinical benefit of androgen-deprivation therapy (ADT), the majority of patients with advanced prostate cancer (PCa) ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we identified thioesterase superfamily member 6 (THEM6) as a marker of ADT resistance...
ORGANISM(S): Homo sapiens (Human) 
2021-12-11 | PXD024456 | Pride
Castration-resistant prostate cancer Cancer metabolism Endoplasmic reticulum Cancer proteomics 
ProteomicsTHEM6-mediated lipid remodelling sustains stress resistance in cancer (Part3 : THEM6 KO in LNCaP AI)
Despite the clinical benefit of androgen-deprivation therapy (ADT), the majority of patients with advanced prostate cancer (PCa) ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we identified thioesterase superfamily member 6 (THEM6) as a marker of ADT resistance...
ORGANISM(S): Homo sapiens (Human) 
2021-12-11 | PXD024433 | Pride
Castration-resistant prostate cancer Cancer metabolism Endoplasmic reticulum Cancer proteomics 
UnknownPersistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.
Not available
S-EPMC4721903 | biostudies-literature
MetabolomicsGNPS - Absent expansion of Axin2 hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in regeneration
Background & Aims: Mouse models of lineage tracing have helped to describe the important subpopulations of hepatocytes responsible for liver regeneration. However, conflicting results have been obtained from different models. Here we aimed to reconcile these conflicting reports by repeating a key li...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2023-01-18 | MSV000091082 | GNPS
UnknownGlobal, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Not available
S-EPMC6227755 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
UnknownAspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213 | biostudies-literature
UnknownConvalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538 | biostudies-literature
UnknownBaricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998 | biostudies-literature
Sort   by:  
 Page size